Classes
DEA Class; Rx
Common Brand Names; Daypro
NSAIDs
Description
NSAID of the propionic acid class; once daily administration
Used for osteoarthritis and rheumatoid arthritis in adults; also used in pediatric patients as young as 6 years for juvenille idiopathic arthritis (JIA)
All NSAIDs may cause an increased risk of serious gastrointestinal or cardiovascular events; use lowest effective dose for the shortest possible duration
Indications
Contraindications
Absolute: ASA allergy, CABG
Relative: bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, SLE, ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)
Adverse Effects
Edema
Rash
Abdominal pain
Anorexia
Constipation
Diarrhea
Indigestion
Nausea/Vomiting
GI ulcer
Gross bleeding with perforation
Heartburn
Anemia
LFT’s increased
Tinnitus
Dysuria, Increased frequency of urination
Myocardial infarction (<2%)
Warnings
Use caution in asthma (bronchial), CHF, fluid retention, cardiac disease, severe hepatic impairment, hypertension, renal impairment
Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include the elderly, or those with impaired renal function, hypovolemia, heart failure, liver dysfunction, salt depletion, and individuals taking diuretics, ACE inhibitors, or ARBs
Factors that increase risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status
May cause drowsiness, dizziness, blurred vision, and other neurologic effects, which may impair physical or mental abilities; discontinue use and perform ophthalmologic exam with blurred or diminished vision occur
Pregnancy and Lactation
Pregnancy
Use of NSAIDs can cause premature closure of fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment
Because of these risks, limit dose and duration of use between about 20 and 30 weeks of gestation, and avoid use at about 30 weeks of gestation and later in pregnancy
Lactation
Naproxen and diphenhydramine are excreted in human breast milk; effect on infant unknown; not recommended
Maximum Dosage
Oxaprozin: 1800 mg/day or 26 mg/kg/day PO, whichever is lower; oxaprozin potassium: 1200 mg/day PO.
Oxaprozin: 1800 mg/day or 26 mg/kg/day PO, whichever is lower; oxaprozin potassium: 1200 mg/day PO.
Oxaprozin: 1200 mg/day PO; oxaprozin potassium: safety and efficacy have not been established.
>= 6 years: Oxaprozin: 1200 mg/day PO; oxaprozin potassium: safety and efficacy have not been established.
How supplied
Tablet
- 600mg